查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1572215

細菌性陰道炎治療藥物市場：按藥物類型、藥物形式、分銷管道、患者屬性和最終用戶分類 - 全球預測 2025-2030

Bacterial Vaginosis Drugs Market by Drug Type (Over-the-counter Drugs, Prescription Drugs), Drug Form (Capsules, Gels, Tablets), Distribution Channel, Patient Demographics, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年細菌性陰道炎治療藥物市場價值為87303萬美元，預計到2024年將達到92192萬美元，複合年成長率為5.88%，到2030年將達到130320萬美元，預計將達到1000萬美元。

細菌性陰道炎藥物市場包括多種用於治療細菌性陰道炎（BV）的藥物，細菌性陰道炎是一種由陰道菌叢失衡引起的常見陰道疾病。這個市場的促進因素是解決高盛行率的問題，特別是對育齡婦女的影響，以及對有效、快速和安全治療的需求。主要用途包括口服和外用製劑中的抗生素和抗菌藥物，如甲硝唑和克林黴素。最終用途包括醫院、診所和藥局，商業選擇擴大了可用性。主要影響因素包括對婦女健康問題認知的提高、醫療保健支出的增加以及藥物開發技術的進步。鑑於人們對抗生素抗藥性的擔憂日益增加，最新的商機凸顯了非抗生素療法和益生菌的開發潛力。此外，利用 DNA 定序技術的個人化醫療創新使我們能夠根據每個人的微生物群量身定做治療方案，以獲得更有效的結果。

主要市場統計
基準年[2023] 87303萬美元
預測年份 [2024] 9.2192億美元
預測年份 [2030] 13.032 億美元
複合年成長率（%） 5.88%

儘管有這些機會，市場仍面臨重大限制，例如細菌性陰道炎復發會影響治療效果，需要進一步研究長期解決方案。新興市場的恥辱感和對陰道健康問題缺乏認知也對市場滲透構成了挑戰。此外，嚴格的監管要求和與藥物開發相關的高成本可能會阻礙新療法進入市場。創新的治療領域包括探索微生物組在維持陰道健康中的作用、開發新型益生元和益生菌治療方法，以及用於早期診斷和提高患者依從性的數位健康工具。市場競爭激烈且充滿活力，需要不斷適應不斷發展的科學發現和患者需求。以客戶為中心的方法，優先考慮患者教育和與醫療保健專業人員的合作，有助於推動業務成長並實現有效的市場滲透。

市場動態：揭示快速發展的細菌性陰道炎治療市場的關鍵市場洞察

細菌性陰道炎藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球育齡婦女細菌性陰道炎症率不斷上升
    • 對細菌性陰道炎有效治療的認知和需求不斷成長
    • 細菌性陰道炎治療藥物研發進展
    • 擴大發展中地區的醫療基礎設施以支持細菌性陰道炎的治療
  • 市場限制因素
    • 新興市場的認知有限和誤診影響了治療率
    • 圍繞細菌性陰道炎的恥辱和社會禁忌影響患者接受治療的意願
  • 市場機會
    • 開拓有針對性的行銷策略，以提高女性對細菌性陰道炎和可用治療方法的認知
    • 利用遠端醫療平台提供便利的細菌性陰道炎諮詢和處方服務。
    • 進行教育宣傳活動以消除細菌性陰道炎並鼓勵及時的醫療干預
  • 市場挑戰
    • 不同醫療保健系統細菌性陰道炎治療的報銷政策不一致
    • 來自學名藥的激烈競爭正在減少品牌細菌性陰道炎藥物製造商的市場佔有率和盈利。

波特的五力：駕馭細菌性陰道炎藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解細菌性陰道炎治療藥物市場的外部影響

外部宏觀環境因素在塑造細菌性陰道炎治療藥物市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解細菌性陰道炎治療藥物市場的競爭狀況

對細菌性陰道炎治療藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣細菌性陰道炎治療藥物市場供應商的績效評估

FPNV 定位矩陣是評估細菌性陰道炎治療藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃細菌性陰道炎治療藥物市場的成功之路

對細菌性陰道炎治療藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球育齡婦女細菌性陰道炎症率增加
      • 對細菌性陰道炎有效治療方法的認知和需求不斷成長
      • 細菌性陰道炎治療藥物研發進展
      • 擴大開發中地區的醫療基礎設施以支持細菌性陰道炎的治療
    • 抑制因素
      • 缺乏認知和誤診影響新興市場的治療率
      • 圍繞細菌性陰道炎的恥辱和社會禁忌影響患者接受治療的意願
    • 機會
      • 制定有針對性的行銷策略，以提高女性對細菌性陰道炎和可用治療方法的認知
      • 利用遠端醫療平台方便獲得細菌性陰道炎諮詢和處方箋
      • 進行教育宣傳活動，消除細菌性陰道炎的污名並鼓勵及時的醫療干預
    • 任務
      • 不同醫療保健系統的細菌性陰道炎治療報銷政策不一致
      • 來自學名藥的激烈競爭降低了品牌細菌性陰道炎藥物製造商的市場佔有率和盈利
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類型分類的細菌性陰道炎治療藥物市場

  • 非處方藥
    • 防腐劑
    • 益生菌
  • 處方藥
    • 口服抗生素
    • 外用抗生素

第7章依劑型分類的細菌性陰道炎治療藥物市場

  • 膠囊
  • 凝膠
    • 藥用凝膠
    • 非藥物凝膠
  • 藥片
    • 發泡
    • 緩釋片
    • 速效錠劑

第8章細菌性陰道炎治療藥物市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章細菌性陰道炎治療藥物市場患者細分

  • 成人
  • 長老
  • 青少年

第10章細菌性陰道炎治療藥物市場：依最終用戶分類

  • 診所
  • 居家護理
  • 醫院

第11章 北美和南美細菌性陰道炎治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太細菌性陰道炎治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲細菌性陰道炎治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C0104

The Bacterial Vaginosis Drugs Market was valued at USD 873.03 million in 2023, expected to reach USD 921.92 million in 2024, and is projected to grow at a CAGR of 5.88%, to USD 1,303.20 million by 2030.

The market for bacterial vaginosis drugs encompasses a range of therapeutics used to treat bacterial vaginosis (BV), a common vaginal condition caused by an imbalance in the vaginal microbiota. This market is driven by the necessity to address high prevalence rates, particularly impacting women of childbearing age, and the demand for effective, fast-acting, and safe treatments. Key applications involve antibiotics and antimicrobial drugs, such as metronidazole and clindamycin, leveraged in both oral and topical forms. The end-use scope spans across hospitals, clinics, and drug stores, with over-the-counter options expanding accessibility. Key influencing factors include the rising awareness of women's health issues, increased healthcare expenditure, and ongoing advancements in drug development technologies. The latest opportunities highlight the potential in developing non-antibiotic therapies and probiotics, given the increasing concern over antibiotic resistance. Innovations in personalized medicine, leveraging DNA sequencing technologies, can also tailor treatments to individual microbiomes for more effective outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 873.03 million
Estimated Year [2024] USD 921.92 million
Forecast Year [2030] USD 1,303.20 million
CAGR (%) 5.88%

Despite these opportunities, the market faces significant limitations, such as the recurrence of BV, which undermines treatment efficacy and necessitates further research into long-term solutions. The stigmatization of vaginal health issues and lack of awareness in developing regions also challenge market penetration. Moreover, stringent regulatory requirements and the high costs associated with drug development can impede the entry of novel therapeutics into the market. Areas ripe for innovation include exploring the microbiome's role in maintaining vaginal health and developing novel prebiotic and probiotic treatments, while also harnessing digital health tools for early diagnosis and improved patient compliance. The bacterial vaginosis drugs market is competitive and dynamic, requiring continuous adaptation to evolving scientific discoveries and patient needs. A customer-centric approach, prioritizing patient education and collaboration with healthcare professionals, can drive business growth and ensure effective market penetration.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bacterial Vaginosis Drugs Market

The Bacterial Vaginosis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of bacterial vaginosis among women of reproductive age globally
    • Growing awareness and demand for effective treatments for bacterial vaginosis
    • Advancements in pharmaceutical research and development for bacterial vaginosis drugs
    • Expansion of healthcare infrastructure in developing regions supporting bacterial vaginosis treatments
  • Market Restraints
    • Limited awareness and misdiagnosis in emerging markets affecting treatment rates
    • Stigma and social taboos surrounding bacterial vaginosis impacting patient willingness to seek treatment
  • Market Opportunities
    • Development of targeted marketing strategies to raise awareness about bacterial vaginosis and available treatments among women
    • Leveraging telemedicine platforms to provide easier access to bacterial vaginosis consultations and prescriptions
    • Creating educational campaigns to destigmatize bacterial vaginosis and encourage timely medical intervention
  • Market Challenges
    • Inconsistent reimbursement policies for bacterial vaginosis treatments across different healthcare systems
    • Intense competition from generic drugs reduces market share and profitability for branded bacterial vaginosis drug manufacturers

Porter's Five Forces: A Strategic Tool for Navigating the Bacterial Vaginosis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bacterial Vaginosis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bacterial Vaginosis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bacterial Vaginosis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bacterial Vaginosis Drugs Market

A detailed market share analysis in the Bacterial Vaginosis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bacterial Vaginosis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bacterial Vaginosis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bacterial Vaginosis Drugs Market

A strategic analysis of the Bacterial Vaginosis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bacterial Vaginosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Bacterial Vaginosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Over-the-counter Drugs and Prescription Drugs. The Over-the-counter Drugs is further studied across Antiseptics and Probiotics. The Prescription Drugs is further studied across Oral Antibiotics and Topical Antibiotics.
  • Based on Drug Form, market is studied across Capsules, Gels, and Tablets. The Gels is further studied across Medicated Gels and Non-medicated Gels. The Tablets is further studied across Effervescent Tablets, Extended Release Tablets, and Immediate Release Tablets.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Patient Demographics, market is studied across Adults, Elders, and Teenagers.
  • Based on End User, market is studied across Clinics, Homecare, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of bacterial vaginosis among women of reproductive age globally
      • 5.1.1.2. Growing awareness and demand for effective treatments for bacterial vaginosis
      • 5.1.1.3. Advancements in pharmaceutical research and development for bacterial vaginosis drugs
      • 5.1.1.4. Expansion of healthcare infrastructure in developing regions supporting bacterial vaginosis treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness and misdiagnosis in emerging markets affecting treatment rates
      • 5.1.2.2. Stigma and social taboos surrounding bacterial vaginosis impacting patient willingness to seek treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of targeted marketing strategies to raise awareness about bacterial vaginosis and available treatments among women
      • 5.1.3.2. Leveraging telemedicine platforms to provide easier access to bacterial vaginosis consultations and prescriptions
      • 5.1.3.3. Creating educational campaigns to destigmatize bacterial vaginosis and encourage timely medical intervention
    • 5.1.4. Challenges
      • 5.1.4.1. Inconsistent reimbursement policies for bacterial vaginosis treatments across different healthcare systems
      • 5.1.4.2. Intense competition from generic drugs reduces market share and profitability for branded bacterial vaginosis drug manufacturers
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bacterial Vaginosis Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Over-the-counter Drugs
    • 6.2.1. Antiseptics
    • 6.2.2. Probiotics
  • 6.3. Prescription Drugs
    • 6.3.1. Oral Antibiotics
    • 6.3.2. Topical Antibiotics

7. Bacterial Vaginosis Drugs Market, by Drug Form

  • 7.1. Introduction
  • 7.2. Capsules
  • 7.3. Gels
    • 7.3.1. Medicated Gels
    • 7.3.2. Non-medicated Gels
  • 7.4. Tablets
    • 7.4.1. Effervescent Tablets
    • 7.4.2. Extended Release Tablets
    • 7.4.3. Immediate Release Tablets

8. Bacterial Vaginosis Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Bacterial Vaginosis Drugs Market, by Patient Demographics

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Elders
  • 9.4. Teenagers

10. Bacterial Vaginosis Drugs Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Homecare
  • 10.4. Hospitals

11. Americas Bacterial Vaginosis Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Bacterial Vaginosis Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Bacterial Vaginosis Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca plc
  • 6. Bayer AG
  • 7. Bristol-Myers Squibb Company
  • 8. Eli Lilly and Company
  • 9. Gilead Sciences, Inc.
  • 10. GlaxoSmithKline plc
  • 11. Johnson & Johnson
  • 12. Merck & Co., Inc.
  • 13. Mylan N.V.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Roche Holding AG
  • 17. Sanofi
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. BACTERIAL VAGINOSIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BACTERIAL VAGINOSIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BACTERIAL VAGINOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BACTERIAL VAGINOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BACTERIAL VAGINOSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BACTERIAL VAGINOSIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTISEPTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ORAL ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TOPICAL ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY MEDICATED GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY NON-MEDICATED GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY EFFERVESCENT TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ELDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TEENAGERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 295. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 304. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 313. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 315. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 322. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 324. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR BACTERIAL VAGINOSIS DRUGS MARKET